“This is both an end-to-end cost-reset opportunity and a structural growth engine, especially for medical device and healthcare technology sectors. Beyond cost containment, these investments would catalyze new high-value innovation markets across AI platforms, robotics, medical devices, and data infrastructure,” he said.